연구동향 분석

Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer

김승태 김태원 김규표 김태유 한세원 이지연 임성희 이민영 김해수 박영석 2015년

논문상세정보
인용/피인용
' Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • 내과학
  • colorectalneoplams
  • korea
  • regorafenib
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
1,990 0

0.0%

' Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer' 의 참고문헌

  • Systemic therapy for colorectal cancer
    Meyerhardt JA N Engl J Med 352 : 476 ~ 487 [2005]
  • Systemic therapy for colorectal cancer
    Meyerhardt JA N Engl J Med 352 476-487 [2005]
  • Salvage S-1monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy
    Lee DJ Med Oncol 28 (Suppl 1:) : S291 ~ 294 [2011]
  • Salvage S-1monotherapy in metastatic colorectal cancer patients who failed irinotecan-based or oxaliplatin-based chemotherapy
    Lee DJ Med Oncol 28 Suppl 1: S291-294 [2011]
  • Regorafenib(BAY 73-4506)in advanced colorectal cancer : a phase I study
    Strumberg D Br J Cancer 106 : 1722 ~ 1727 [2012]
  • Regorafenib(BAY 73-4506)in advanced colorectal cancer : a phase I study
    Strumberg D Br J Cancer 106 1722-1727 [2012]
  • Regorafenib(BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
    Wilhelm SM Int J Cancer 129 : 245 ~ 255 [2011]
  • Regorafenib(BAY 73-4506) : a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
    Wilhelm SM Int J Cancer 129 245-255 [2011]
  • Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3trial
    Grothey A Lancet 381 : 303 ~ 312 [2013]
  • Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3trial
    Grothey A Lancet 381 303-312 [2013]
  • Regorafenib in combination with FOLFOX or FOLFIRI as first-or second-line treatment of colorectal cancer : results of a multicenter, phase Ib study
    Schultheis B Ann Oncol 24 : 1560 ~ 1567 [2013]
  • Regorafenib in combination with FOLFOX or FOLFIRI as first-or second-line treatment of colorectal cancer : results of a multicenter, phase Ib study
    Schultheis B Ann Oncol 24 1560-1567 [2013]
  • Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma : multicentre, openlabel, phase II safety study
    Bruix J Eur J Cancer 49 : 3412 ~ 3419 [2013]
  • Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma : multicentre, openlabel, phase II safety study
    Bruix J Eur J Cancer 49 3412-3419 [2013]
  • Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
    Van Cutsem E J Clin Oncol 25 : 1658 ~ 1664 [2007]
  • Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
    Van Cutsem E J Clin Oncol 25 1658-1664 [2007]
  • Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma
    Kang EJ Asia Pac J Clin Oncol 6 : 286 ~ 291 [2010]
  • Mitomycin-C, 5-fluorouracil, and leucovorin as a salvage therapy in patients with metastatic colorectal adenocarcinoma
    Kang EJ Asia Pac J Clin Oncol 6 286-291 [2010]
  • Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    de Gramont A J Clin Oncol 18 : 2938 ~ 2947 [2000]
  • Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer
    de Gramont A J Clin Oncol 18 2938-2947 [2000]
  • Global cancer statistics, 2002
    Parkin DM CA Cancer J Clin 55 : 74 ~ 108 [2005]
  • Global cancer statistics, 2002
    Parkin DM CA Cancer J Clin 55 74-108 [2005]
  • Gemcitabine and capecitabine as third-or later-line therapy for refractory advanced colorectal cancer : a retrospective study
    Salgado M Anticancer Res 33 : 4089 ~ 4096 [2013]
  • Gemcitabine and capecitabine as third-or later-line therapy for refractory advanced colorectal cancer : a retrospective study
    Salgado M Anticancer Res 33 4089-4096 [2013]
  • FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer : a randomized GERCOR study
    Tournigand C J Clin Oncol 22 : 229 ~ 237 [2004]
  • FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer : a randomized GERCOR study
    Tournigand C J Clin Oncol 22 229-237 [2004]
  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib(GRID) : an international, multicentre, randomised, placebo-controlled, phase 3 trial
    Demetri GD Lancet 381 : 295 ~ 302 [2013]
  • Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib(GRID) : an international, multicentre, randomised, placebo-controlled, phase 3 trial
    Demetri GD Lancet 381 295-302 [2013]
  • Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer
    Kim ST Asia Pac J Clin Oncol 7 : 82 ~ 87 [2011]
  • Capecitabine monotherapy as salvage treatment after failure of chemotherapy containing oxaliplatin and irinotecan in patients with metastatic colorectal cancer
    Kim ST Asia Pac J Clin Oncol 7 82-87 [2011]
  • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin(FOLFOX4)for previously treated metastatic colorectal cancer : results from the Eastern Cooperative Oncology Group Study E3200
    Giantonio BJ J Clin Oncol 25 : 1539 ~ 1544 [2007]
  • Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin(FOLFOX4)for previously treated metastatic colorectal cancer : results from the Eastern Cooperative Oncology Group Study E3200
    Giantonio BJ J Clin Oncol 25 1539-1544 [2007]
  • Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer : results of a randomized phase II trial
    Kabbinavar FF J Clin Oncol 23 : 3697 ~ 3705 [2005]
  • Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer : results of a randomized phase II trial
    Kabbinavar FF J Clin Oncol 23 3697-3705 [2005]
  • A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer
    Kim SY Invest New Drugs 27 : 269 ~ 274 [2009]
  • A phase II study of S-1 plus irinotecan and oxaliplatin in heavily-treated patients with metastatic colorectal cancer
    Kim SY Invest New Drugs 27 269-274 [2009]
  • A phase I dose-escalation study of regorafenib(BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors
    Mross K Clin Cancer Res 18 : 2658 ~ 2667 [2012]
  • A phase I dose-escalation study of regorafenib(BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors
    Mross K Clin Cancer Res 18 2658-2667 [2012]